​For half a year, medical commercial bribery cases will be notified and included in the credit rating of pharmaceutical companies!

On May 26, the National Health Commission announced the recent work of ensuring supply and price stabilization of shortages of medicines, which mentioned an important piece of information that is closely related to pharmaceutical companies.

Before we talk about the main text, let’s review one thing.

Later, I shared with you in January this year.

In addition, the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment", which has been prepared by the National Medical Insurance Administration since 2019, has been implemented in the drug price and recruitment credit evaluation system at the beginning of this year.

The specific requirements are as follows: For those who have not submitted a written commitment, from April 1, 2021, the provincial centralized procurement agencies will no longer accept their new bids or online applications; since June 1, they have won the bid If there are other companies to guarantee the supply of pharmaceutical products or have alternatives to meet clinical needs, they should be removed from the network.

In the public announcement of the Health Commission on the 26th, it was mentioned that supervision and law enforcement should be further strengthened, and various illegal drug operations should be severely investigated and dealt with, including the comprehensive implementation of the establishment of a medical price and recruitment credit evaluation system, under the guidance of the National Medical Insurance Administration.

The "Guiding Opinions on Establishing a Pharmaceutical Price and Recruitment Credit Evaluation System" was officially released by the National Medical Insurance Bureau on September 16 last year.